Fig. 3From: Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspectiveProbabilistic cost-effectiveness scatterplot. Each dot represents the ICER for 1 simulationBack to article page